广泛期小细胞肺癌巩固性胸部放疗联合阿替利珠单抗维持治疗的2期随机临床试验TREASURE
这项多中心开放标签2期随机试验纳入诱导化疗免疫治疗后至少疾病稳定的广泛期小细胞肺癌患者,随机接受阿替利珠单抗维持联合巩固性胸部放疗(30 Gy/10次)或阿替利珠单抗维持 alone。联合组中位OS数值更短(6.7 vs 13.4个月),PFS相似,但严重不良事件和致死性结局显著增加,因安全性担忧提前终止招募。
要点
- 巩固性胸部放疗联合免疫维持未改善OS,联合组中位OS数值更短。
- 联合组严重不良事件和致死性结局显著高于单药维持组。
- 毒性可能与放疗诱导淋巴细胞耗竭促进感染相关。
核心结论
- 在未选择的广泛期小细胞肺癌患者中,巩固性胸部放疗联合免疫维持增加毒性且无生存获益。
研究设计与样本
- 多中心开放标签2期随机临床试验,2020年9月至2022年8月在德国和奥地利招募,68例患者随机1:1分组。
临床怎么用
- 不推荐在未选择的广泛期小细胞肺癌患者中常规联合巩固性胸部放疗与免疫维持治疗。
- 需谨慎选择患者并进一步研究识别可能获益且风险可控的人群。
局限性
- 因安全性担忧提前终止招募,样本量有限(68例随机)。
- 开放标签设计。
- 事后生存更新分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Chemoimmunotherapy followed by immunotherapy maintenance is the standard first-line treatment for extensive-stage small cell lung cancer (ES-SCLC), yet data regarding efficacy and safety of consolidative thoracic radiotherapy (TRT) are lacking. OBJECTIVE: To determine whether combining consolidative TRT with immunotherapy maintenance in ES-SCLC is safe and improves patients' overall survival (OS) and progression-free survival (PFS). DESIGN, SETTINGS, AND PARTICIPANTS: This was a multicenter open-label phase 2 randomized clinical trial recruiting patients from September 2020 to August 2022 in Germany and Austria, with the last follow-up visit in September 2024. Eligible patients had ES-SCLC with at least stable disease after induction chemoimmunotherapy (carboplatin-etoposide-atezolizumab). Although the database was locked in April 2025, a post hoc survival update was performed in April 2026. Data were analyzed from April 2025 to April 2026. INTERVENTIONS: Randomized (1:1) to either atezolizumab maintenance combined with consolidative TRT (30 Gy in 10 fractions) (arm A) or atezolizumab maintenance alone (arm B). MAIN OUTCOME AND MEASURE: OS (time from randomization to death due to any cause). RESULTS: Of 96 patients assessed for eligibility, 68 patients were randomized; recruitment was prematurely terminated due to safety concerns. Median OS in the combination arm was numerically shorter compared to atezolizumab only (6.7 months [95% CI, 5.1-9.0] vs 13.4 months [95% CI, 10.7-17.5]; HR, 1.55 [95% CI, 0.90-2.69]; P = .34), while median PFS was similar (2.4 months [95% CI, 1.3-3.9] vs 2.6 months [95% CI, 1.2-3.9]; HR, 0.92 [95% CI, 0.54-1.55]; P = .85). TRT plus atezolizumab was accompanied by higher frequency of severe adverse events (SAEs) (19 patients [61.3%] vs 6 patients [18.2%]; P < .001) and fatal outcomes (6 patients [19.4%] vs 1 patient [3.0%]; P = .04). Safety analysis revealed predominance of infection and respiratory disorder-related SAEs, possibly facilitated by a depletion of lymphocytes observed specifically in patients after TRT, and by a lower single breath diffuse capacity of the lungs for carbon monoxide in patients with fatal AEs in arm A. No further risk factors were identified, given that baseline characteristics were well balanced between both arms and between patients with and without SAEs, including fatal SAEs. CONCLUSIONS AND RELEVANCE: In this randomized clinical trial, TRT combined with immunotherapy increased toxic effects in unselected patients with ES-SCLC without survival benefit, presumably due to radiation-induced lymphocyte depletion facilitating infections. Cautious patient selection and further investigation to identify those who may benefit without undue risk are required. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04462276.
引用
- Bozorgmehr F, Chung I, Behnisch R, et al. Consolidative Thoracic Radiotherapy With Atezolizumab Maintenance in Extensive-Stage Small Cell Lung Cancer: The Phase 2 TREASURE Randomized Clinical Trial (AIO-TRK-0320). JAMA Oncol. 2026. PMID: 42424047. doi:10.1001/jamaoncol.2026.2330
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。